Quick Summary / Key Disclosed Facts
- Offer Document Date: Updated Draft Red Herring Prospectus-I (U-DRHP-I) dated August 7, 2026.
- Total Proposed Offer Size: Up to ₹48,000.00 million (₹4,800 crore).
- Proposed Fresh Issue: Up to ₹18,000.00 million (₹1,800 crore).
- Proposed Offer for Sale (OFS): Up to ₹30,000.00 million (₹3,000 crore) by promoter selling shareholder BCP Asia II Topco VIII Pte. Ltd.
- Face Value: ₹1 per equity share.
- Proposed Listing: BSE and NSE.
- FY2026 Revenue from Operations (Consolidated): ₹20,414.20 million (₹2,041.42 crore).
- FY2026 Restated Profit: ₹2,069.46 million (₹206.95 crore).
- Offering Parameters: Price band, lot size, and issue timeline are not yet finalized in the reviewed draft filing.
1. What AGS Health Filed
AGS Health Limited has filed an Updated Draft Red Herring Prospectus-I (U-DRHP-I) dated August 7, 2026, with the Securities and Exchange Board of India (SEBI) for a proposed initial public offering (IPO) on Indian stock exchanges.
The reviewed offer document proposes a total public issue aggregating up to ₹48,000.00 million (₹4,800 crore), consisting of a Fresh Issue of equity shares of up to ₹18,000.00 million (₹1,800 crore) and an Offer for Sale (OFS) of equity shares aggregating up to ₹30,000.00 million (₹3,000 crore) by the promoter selling shareholder, BCP Asia II Topco VIII Pte. Ltd. The equity shares have a face value of ₹1 each and are proposed to be listed on both BSE and NSE.
In the reviewed draft filing, the exact number of equity shares to be offloaded under the Offer for Sale remains to be finalized based on the book-built offer price.
2. Proposed IPO Structure
The capital structure disclosed in the Updated DRHP-I dated August 7, 2026, outlines the following primary components:
- Fresh Issue: Up to ₹18,000.00 million (₹1,800 crore) of newly issued equity shares.
- Offer for Sale (OFS): Up to ₹30,000.00 million (₹3,000 crore) by BCP Asia II Topco VIII Pte. Ltd.
- Total Public Issue: Up to ₹48,000.00 million (₹4,800 crore).
- Pre-IPO Placement Consideration: The company, in consultation with the Book Running Lead Managers, may consider a Pre-IPO Placement aggregating up to ₹3,600.00 million (₹360 crore) prior to filing the Red Herring Prospectus (RHP). If such a Pre-IPO Placement is completed, the amount raised will be reduced from the Fresh Issue size, subject to applicable filing terms.
3. What AGS Health Does
AGS Health Limited is a technology-first Revenue Cycle Management (RCM) solutions provider dedicated to serving healthcare providers in the United States. The company operates in a single primary reportable segment: Revenue Cycle Management.
The company's end-to-end service capabilities span three core operational pillars:
1. Front-End Revenue Optimization
Covers patient access services, patient eligibility and insurance verification, financial clearance, and patient financial engagement solutions prior to clinical care delivery.
2. Mid-Cycle Revenue Optimization
Encompasses care management capabilities, medical coding and clinical documentation solutions, and revenue integrity verification during and immediately following patient care.
3. Back-End Revenue Optimization
Includes claims processing and payment posting, denials management and underpayment resolution, insurance follow-up and collections, and patient billing and collections.
The company delivers solutions to healthcare systems, hospitals, and physician groups across various geographic regions in the United States.
4. FY2026 Financial Snapshot
The table below summarizes the key financial metrics disclosed in the Updated DRHP-I for FY2026. (Note: FY2026 figures represent consolidated financial statements of the issuer, whereas FY2025 and FY2024 figures in the abridged section represent standalone financials of the issuer; hence they are not directly like-for-like.)
| Financial Metric | FY2026 (Consolidated) |
|---|---|
| Revenue from Operations | ₹20,414.20 Million (₹2,041.42 Cr) |
| EBITDA | ₹7,801.72 Million (₹780.17 Cr) |
| Adjusted EBITDA | ₹7,851.94 Million (₹785.19 Cr) |
| Restated Profit for the Year | ₹2,069.46 Million (₹206.95 Cr) |
| Net Worth | ₹45,516.13 Million (₹4,551.61 Cr) |
| Total Borrowings | ₹42,388.10 Million (₹4,238.81 Cr) |
| Basic & Diluted EPS | ₹6.30 per share |
5. Objects of the Fresh Issue
According to the Updated DRHP-I, the company proposes to utilize the gross proceeds from the Fresh Issue for:
- ₹16,000.00 million (₹1,600 crore): Prepayment and/or repayment, in full or in part, of certain outstanding borrowings availed by two wholly owned indirect subsidiaries: AGS Health BCP LLC and AGS Health BCP Holdings, Inc.
- General Corporate Purposes: The remaining applicable proceeds will be allocated towards general corporate purposes, subject to the statutory limits and final amounts disclosed in the official prospectus.
6. Customer Concentration & Business Profile
The company's customer base exhibits meaningful concentration among top healthcare accounts. According to proforma financial disclosures in the filing:
- Top 5 Customers: Represented 40.46% of proforma revenue from operations in FY2026 (compared to 40.67% in FY2025 and 41.49% in FY2024).
Operational Footprint (FY2026)
- Total Customers: 149 healthcare client accounts, including 82 hospitals and health systems.
- Global Workforce: 15,895 employees across 10 global delivery sites.
- Workforce Diversity & Retention: Women represented 46.87% of the global workforce, with an employee voluntary attrition rate of 23.27% in FY2026.
7. Key Things Investors Should Note
Prospective investors should evaluate the operational and capital risk factors outlined in the offer document, including:
- Substantial Borrowings: The issuer carried total borrowings of ₹42,388.10 million as of March 31, 2026, a majority of which the Fresh Issue seeks to repay.
- U.S. Healthcare Regulatory & Market Exposure: Revenues are heavily dependent on spending, reimbursement policies, and regulatory dynamics across healthcare providers in the United States.
- Customer Concentration: Top five client relationships generate over 40% of proforma revenues.
- First Public Issue: Because this is the company's initial public offering, there has been no prior public trading market for the equity shares. The final issue price should not be taken as indicative of future trading performance.
8. Details Not Yet Finalized / Announced
Offering Parameters Awaiting Final RHP
The following offering parameters are not available or not finalized in the reviewed Updated DRHP-I and will be determined prior to issue launch:
- Price Band & Floor/Cap Price: Not available / not finalized in the reviewed source.
- Lot Size & Minimum Investment: Not available / not finalized in the reviewed source.
- Anchor Investor Allocation Date: Not available / not finalized in the reviewed source.
- Issue Opening Date & Closing Date: Not available / not finalized in the reviewed source.
- Basis of Allotment Date & Listing Date: Not available / not finalized in the reviewed source.
- Final Share Count under Fresh Issue & OFS: Not available / will be calculated upon price band finalization.
9. Primary Source
Primary source: AGS Health Limited, Updated Draft Red Herring Prospectus-I / Draft Abridged Prospectus dated August 7, 2026.
10. Important Disclaimer
Important Disclaimer: Digital Arthalaya is an independent educational and financial news publication. This article is provided for informational purposes only and does not constitute investment advice, an IPO subscription recommendation, or a guarantee of returns. Investors should review applicable offer documents, risk factors, and their own financial circumstances before making investment decisions.